---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026810"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T20:51:52.195837+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva reports Q4 2022 royalties of $54.7M, pre-tax loss of $64.7M on $85.4M fair-value decline

## Summary
- Gross royalty revenues of $54.7M from GSK for RELVAR/BREO and ANORO ELLIPTA in Q4 2022.
- Income before taxes was a loss of $64.7M vs. income of $56.5M in Q4 2021, driven by $85.4M decline in fair value of investments.
- Net product sales of $14.6M from GIAPREZA and XERAVA in Q4 2022.
- Board authorized $100M share repurchase program; $30M convertible debt facility with Armata closed in January 2023.
- FDA granted priority review for SUL-DUR NDA; PDUFA date May 29, 2023.

## SEC filing metadata
- accession: 0001104659-23-026810
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465923026810/0001104659-23-026810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465923026810/tm238049d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026810
- JSON: https://secwatch.observer/filing/0001104659-23-026810.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026810.txt

## Key facts
- Earnings Releases
  Innoviva, Inc. reported financial results for the fourth quarter ended December 31, 2022.
  - Period: the fourth quarter ended December 31, 2022
  - Result: reported results
  source text: On February 28, 2023, Innoviva, Inc. (the "Company") issued a press release regarding its results of operations and financial condition for the quarter ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000110465923026810/0001104659-23-026810-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.